Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant

29 Jul 2023

Abstract excerpt

OBJECTIVES: To characterize a blaCMY variant associated with ceftazidime/avibactam resistance from a serially collected Escherichia coli isolate. METHODS: A patient with an intra-abdominal infection due to recurrent E. coli was treated with ceftazidime/avibactam. On Day 48 of ceftazidime/avibactam therapy, E. coli with a ceftazidime/avibactam MIC of >256 mg/L was identified from abdominal drainage. Illumina and...

Topics

Join the communities discussing this publication.

Antibiotic Resistance in Bacteria
Antibiotics Pharmacokinetics and Efficacy
Infections and bacterial resistance

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 37574665
DOI: 10.1093/jac/dkad249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variantPMID 37574665Read ↗

High-level ceftazidime-avibactam resistance in <i>Escherichia coli</i> conferred by the novel plasmid-mediated beta-lactamase CMY-185 variantSemantic proximity Read ↗

Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coliSemantic proximity Read ↗

A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant EscherichiacoliSemantic proximity Read ↗

Ceftazidime–Avibactam Resistance in <i>Escherichia coli</i> Primarily Mediated by <i>bla</i> <sub>NDM-5</sub> with Emergent Ceftazidime–Avibactam/Aztreonam Resistance Linked to <i>bla</i> <sub>CMY-42</sub> VariantsSemantic proximity Read ↗

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185Semantic proximity Read ↗

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing EnterobacteriaceaeSemantic proximity Read ↗

Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baselineSemantic proximity Read ↗

In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC β-lactamase in Klebsiella aerogenes.Semantic proximity Read ↗

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactamSemantic proximity Read ↗

Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017Semantic proximity Read ↗

Rapid Emergence of Resistance to Broad-Spectrum Direct Antimicrobial Activity of AvibactamSemantic proximity Read ↗

Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative BacteriaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.